NRX Pharmaceuticals (NRXP) EPS (Basic) Growth (3y) (2020 - 2026)
NRX Pharmaceuticals (NRXP) EPS (Basic) Growth (3y) (2020 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Basic) Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,741.39 Bn | 66,741.11 Bn | - | 53.55% |
| 2 | Nanobiotix | 1,913.26 Bn | 1,913.20 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.02 Bn | 466.23 Bn | 1.35 Bn | 37.73% |
| 5 | Vertex Pharmaceuticals | 122.17 Bn | 114.92 Bn | 2.59 Bn | 14.29% |
| 6 | Regeneron Pharmaceuticals | 69.85 Bn | 61.10 Bn | 3.31 Bn | -2.89% |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.60 Bn | 50.42 Bn | 1.41 Bn | 86.43% |
| 9 | Alnylam Pharmaceuticals | 37.39 Bn | 34.38 Bn | 959.66 Mn | 45.89% |
| 10 | NRX Pharmaceuticals | 117.24 Mn | 110.54 Mn | 437,000.00 | 36.06% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 36.06% |
| Dec 31, 2025 | 48.24% |
| Sep 30, 2025 | 48.25% |
| Jun 30, 2025 | 41.94% |
| Mar 31, 2025 | 55.32% |
| Dec 31, 2024 | 67.23% |
| Sep 30, 2024 | 66.26% |
| Jun 30, 2024 | 77.82% |
| Mar 31, 2024 | 40.04% |
| Dec 31, 2023 | 64.64% |
| Sep 30, 2023 | 65.95% |
| Jun 30, 2023 | -70.23% |
| Mar 31, 2023 | -37.72% |
| Dec 31, 2022 | -136.21% |
| Sep 30, 2022 | -103.83% |
| Jun 30, 2022 | -54.48% |
| Mar 31, 2022 | -79.72% |
| Sep 30, 2021 | -275.17% |
| Jun 30, 2021 | -1,116.91% |
| Mar 31, 2021 | -286.29% |